Hepatoprotective Effects of Aureobasidium pullulans Derived β 1,3–1,6 Glucans in a Murine Model of Non-alcoholic Steatohepatitis

• DOI: 10.1016/j.jceh.2022.06.008
• Publication Date: 2022-06-28T00:19:12Z
• Authors: Nobunao Ikewaki; Gary A. Levy; Gene Kurosawa; Masaru Iwasaki; Vidyasagar D. Ded...; Suryaprakash Vaddi; Rajappa Senthilkumar; Senthilkumar Preethy; Samuel J.K. Abraham
• Keywords: Steatohepatitis; Steatosis; Sirius Red; Aureobasidium pullulans

<h3>Background</h3> Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are highly prevalent conditions characterized by inflammation fibrosis of the liver, which can progress to cirrhosis hepatocellular carcinoma if left untreated. Conventional modalities mainly symptomatic, with no definite solution. Beta-glucan-based biological response modifiers a potential strategy in lieu their beneficial metabolic effects. <i>Aureobasidium pullulans</i> strains AFO-202 N-163 beta-glucans were evaluated for anti-fibrotic anti-inflammatory hepatoprotective potentials NASH animal model this study. <h3>Methods</h3> In STAM™ murine NASH, five groups studied 8 weeks: (1) vehicle (RO water), (2) beta-glucan; (3) beta-glucan, (4) AFO-202+N-163 (5) telmisartan (standard pharmacological intervention). Evaluation biochemical parameters plasma hepatic histology including Sirius red staining F4/80 immunostaining performed. <h3>Results</h3> beta-glucan significantly decreased inflammation-associated cell ballooning steatosis. (<i>P</i> value < 0.05). The combination NAFLD Activity Score (NAS) compared other groups. <h3>Conclusion</h3> This preclinical study supports alone or as preventive therapeutic agent(s), NASH.